The Association of Interstitial Lung Disease with Rheumatoid Arthritis_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

LiLinwei , DuJing , DengYan , ZuPing , HeTailing , YuanYuru ,  LiangBinmiao

Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan, 610041, China;

Corresponding author：

LiangBinmiao, Email: liangbinmiao@163.com

Keywords：

Rheumatoid arthritis; Interstitial lung disease; Risk factors

DOI：

10.7507/1671-6205.2015042

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To evaluate the prevalence of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA),and explore the association of ILD with RA. Methods Patients who were diagnosed as RA were recruited in the study,and were categorized into a RA-ILD group and a non-ILD group according to high-resolution computed tomography (HRCT).The data of clinical characteristics,serum biomarkers measurement,and pulmonary function test were collected. Logistic regression analysis was performed to evaluate the factors associated with the incidence of ILD in RA. Results A total of 59 patients with RA were enrolled. The incidence of ILD in RA was 42.3%. The rheumatoid factor (RF),carbohydrate antigen 15-3 (CA15-3),carbohydrate antigen12-5 (CA125),inspiratory capacity (IC) and diffusion capacity for carbon monoxide of the lung (D_LCO) were significantly different between two groups (all P<0.05). Multivariate logistic regression analysis revealed that the increased CA15-3 and decreased D_LCO were independent risk factors for ILD in the patients with RA. Conclusions The occurrence of ILD with RA seems very high. CA15-3 and D_LCO may be important risk factors for the incidence of ILD in patients with RA.

Citation： LiLinwei, DuJing, DengYan, ZuPing, HeTailing, YuanYuru, LiangBinmiao. The Association of Interstitial Lung Disease with Rheumatoid Arthritis. Chinese Journal of Respiratory and Critical Care Medicine, 2015, 14(2): 165-167. doi: 10.7507/1671-6205.2015042 Copy

1.	Bergamaschi S, Morato E, BazzoM, et al. Tumor markers are elevated in patients with rheumatoid arthritis and do not indicate present of cancer. Int J Rheum Dis, 2012, 15:179-182.
2.	Young A, Koduri G.Extra-articular manifestations and complications of rheumatoid arthritis.Best Pract Res Clin Rheumatol, 2007, 21:907-927.
3.	Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association1987revisedcriteria for the classification of rheumatoid arthritis. Arthritis Rheum, 1988, 31:315-324.
4.	潘解萍.结缔组织病伴肺间质性疾病的诊治进展. 实用临床医药杂志, 2007, 11:26-28.
5.	Lee HK,Kim DS,Yoo B, et al. Histopa thologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease.Chest,2005, 127:2019-2027.
6.	李小燕, 邵体红, 陈曦等. 类风湿关节炎合并间质性肺病的临床特点. 安徽医学, 2013, 34:127-130.
7.	Bilgici A, Ulusoy H, Kuru O, et al.Pulmonary involvement in rheumatoid arthritis.Rheumatol Int, 2005, 25:429-435.
8.	Habib HM, Eisa AA, Arafat WR, et al. Pulmonary involvement in early rheumatoid arthritis patients. Clin Rheumatol, 2011, 30:217-221.
9.	Lee DM, Schur PH. Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis, 2003, 62:870-874.
10.	van Boekel MA, Vossenaar ER, van den Hoogen FH, et al. Autoantibody systems in rheumatoid arthritis:specificity, sensitivity and diagnostic value. Arthritis Res, 2002, 4:87-93.
11.	Inui N, Enomoto N, Suda T, et al. Anticyclic citrullinated peptide antibodies in lung diseases associated with rheumatoid arthritis. Clin Biochem, 2008, 41:1074-1077.
12.	Korkmaz C, Us T, Kasifoglu T, et al. Anti-cyclic citrullinated pep-tide (CCP) antibodies inpatients with long-standing rheumatoid arthritis and their relationship with extra-articular manifestations. Clin Biochem, 2006, 39:961-965.
13.	Szekanecz E, Sandor Z, Antal-Szalmas P, et al. Increased production of the soluble tumor-associated antigens CA19-9, CA125, andCA15-3 in rheumatoid arthritis:potentialadhesion molecules in synovial inflammation? Ann N Y Acad Sci, 2007, 1108:359-371.
14.	Amoura Z,Duhaut P, Huong DL, et al. Tumor antigen markers for he detection of solid cancers in inflammatory myopathies. Cancer Epidemiol Biomarkers Prev, 2005, 14:1279-1282.
15.	Akira M, Sakatani M, Hara H. Thin-section CT findings in rheumatoid arthritis-associated lung disease:CT patterns and their courses. J Comput Assist Tomogr, 1999, 23:941-948.
16.	Dawson JK, Fewins HE, Desmond J,et al. Predictors of progression of HRCT diagnosed fibrosing alveolitis in patients with rheumatoid arthritis. Ann Rheum Dis,2002, 61:517-521.

1. Bergamaschi S, Morato E, BazzoM, et al. Tumor markers are elevated in patients with rheumatoid arthritis and do not indicate present of cancer. Int J Rheum Dis, 2012, 15:179-182.
2. Young A, Koduri G.Extra-articular manifestations and complications of rheumatoid arthritis.Best Pract Res Clin Rheumatol, 2007, 21:907-927.
3. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association1987revisedcriteria for the classification of rheumatoid arthritis. Arthritis Rheum, 1988, 31:315-324.
4. 潘解萍.结缔组织病伴肺间质性疾病的诊治进展. 实用临床医药杂志, 2007, 11:26-28.
5. Lee HK,Kim DS,Yoo B, et al. Histopa thologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease.Chest,2005, 127:2019-2027.
6. 李小燕, 邵体红, 陈曦等. 类风湿关节炎合并间质性肺病的临床特点. 安徽医学, 2013, 34:127-130.
7. Bilgici A, Ulusoy H, Kuru O, et al.Pulmonary involvement in rheumatoid arthritis.Rheumatol Int, 2005, 25:429-435.
8. Habib HM, Eisa AA, Arafat WR, et al. Pulmonary involvement in early rheumatoid arthritis patients. Clin Rheumatol, 2011, 30:217-221.
9. Lee DM, Schur PH. Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis, 2003, 62:870-874.
10. van Boekel MA, Vossenaar ER, van den Hoogen FH, et al. Autoantibody systems in rheumatoid arthritis:specificity, sensitivity and diagnostic value. Arthritis Res, 2002, 4:87-93.
11. Inui N, Enomoto N, Suda T, et al. Anticyclic citrullinated peptide antibodies in lung diseases associated with rheumatoid arthritis. Clin Biochem, 2008, 41:1074-1077.
12. Korkmaz C, Us T, Kasifoglu T, et al. Anti-cyclic citrullinated pep-tide (CCP) antibodies inpatients with long-standing rheumatoid arthritis and their relationship with extra-articular manifestations. Clin Biochem, 2006, 39:961-965.
13. Szekanecz E, Sandor Z, Antal-Szalmas P, et al. Increased production of the soluble tumor-associated antigens CA19-9, CA125, andCA15-3 in rheumatoid arthritis:potentialadhesion molecules in synovial inflammation? Ann N Y Acad Sci, 2007, 1108:359-371.
14. Amoura Z,Duhaut P, Huong DL, et al. Tumor antigen markers for he detection of solid cancers in inflammatory myopathies. Cancer Epidemiol Biomarkers Prev, 2005, 14:1279-1282.
15. Akira M, Sakatani M, Hara H. Thin-section CT findings in rheumatoid arthritis-associated lung disease:CT patterns and their courses. J Comput Assist Tomogr, 1999, 23:941-948.
16. Dawson JK, Fewins HE, Desmond J,et al. Predictors of progression of HRCT diagnosed fibrosing alveolitis in patients with rheumatoid arthritis. Ann Rheum Dis,2002, 61:517-521.

Chinese Journal of Respiratory and Critical Care Medicine

The Association of Interstitial Lung Disease with Rheumatoid Arthritis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content